Ikke helt, ble utsatt til i morgen 
1 Like
Det er ikke det jeg leser nĂ„r jeg leser pĂ„ hjemmesiden. Ser ikke at det er noen begrensninger til bare diagnostikk her. De nevner spesifikt bĂ„de management og medicinesâŠ
In collaboration with our partners, we are dedicated to improving outcomes for patients all around the world. Itâs a dedication that can be seen in our products and services, providing transformative solutions that improve the management of bladder cancer, as well as helping us become a global leader in the field.
Our vision
Leading change in bladder cancer
For too long patients with bladder cancer have had limited options, leaving them living in fear of recurrence and progression. This is why we are The Bladder Cancer Company and why every single person at Photocure is focused on a single mission â making a continuous, positive impact on the lives of our patients, the people we work with, and society as a whole.
Our mission
To deliver transformative solutions to improve the lives of bladder cancer patients
Our mission is to shape a future where bladder cancer is seen as manageable.
We pride ourselves on our ambition to innovate; to create medicines, medical devices and improved procedures that help healthcare providers deliver improved bladder cancer outcomes to their patients.
We are working to ensure more effective treatment with better patient outcomes is the new standard.
2 Likes
Press Release â Oslo, Norway, October 15, 2025: Photocure ASA
Our partnership with ISC is part of Photocureâs strategic focus on advancing precision diagnostics in uro-oncology. Building on its strong track record and established credibility in bladder cancer diagnostics, Photocure aims to leverage leading innovative technologies to grow a portfolio of complementary diagnostic solutions to address the evolving needs of patients, physicians, and the broader healthcare community.
Diagnostik (Hexvix) og immunterapi fx.(ANKTIVA) adresserer forskellige dele af blÊrekrÊftforlÞbet. PrÊcis diagnostik er en forudsÊtning for korrekt behandling, sÄ de komplementerer hinanden.
Hvis Photocure laver et opkĂžb, vil det sandsynligvis vĂŠre noget, der understĂžtter deres eksisterende platform, og det kan vĂŠre diagnostik, Fluorescerende agenter eller divice nĂŠre lĂžsninger.
1 Like
Hvis ledelsen i Photocure gÄr ut og sier de skal fokusere pÄ tilbakekjÞp og utbytte istedet for Ä pisse bort penger er det veldig mye bedre for aksjonÊrene
9 Likes
The Board of Directors does not propose a dividend payment for 2024⊠Photocure does not expect to pay dividends in the near future.
SĂ„ der kommer nok heller ingen tidlige julegaver i Ă„rđ đ»
1 Like
Vi er i 2026 nÄ, sÄ utbytte for 2025 er vel fremdeles mulig? Kommer det ett stort nok engangsbelÞp kan de jo ogsÄ utbetale et ekstraordinÊrt utbytte 
Dream on
1 Like
A multi-modal approach for decision making in bladder cancer
Bladder cancer remains a major global health challenge, characterized by diagnostic uncertainty, substantial treatment costs and high recurrence rates. Current diagnostic and treatment modalities, including cystoscopy, transurethral resection of bladder tumour and standard histopathology, have limitations, including the inability to detect flat lesions, frequent understaging and interobserver variability, highlighting a crucial need for improved approaches. Advances in artificial intelligence (AI), blue-light cystoscopy, narrow-band imaging, cytology and urinary markers show promise in enhancing early detection and diagnosis
Incomplete resection at initial TURBT remains a major driver of early recurrence in nonâmuscle-invasive bladder cancer
Standard white-light cystoscopy has limited sensitivity for flat lesions such as carcinoma in situ, contributing to understaging and residual disease
Optical enhancement techniques, including fluorescence-guided cystoscopy, improve tumour detection and completeness of resection compared with white light alone
While emerging imaging and molecular approaches are promising, many remain limited by availability, cost, and lack of prospective outcome data.
Optimal decision-making in bladder cancer requires integration of high-quality endoscopic imaging, pathology, and risk stratification
âImproved visualisation at the time of resection has downstream effects on recurrence rates, adjuvant treatment decisions, and surveillance intensity.
= BLC fremstÄr som et klinisk modent verktÞy i kjernen av multimodal beslutningstaking.
6 Likes
Question 1: When was the companyâs APL-1702 approved?
Answer: The Drug Review Center (CDE) of the State Drug Administration has completed
The technical review of APL-1702, the company will accelerate its listing review and approval.
Investor relations are active in order to obtain listing approval as soon as possible. Regarding the follow-up progress, the company will strictly follow the relevant provisions of the âRules for Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchangeâ and other relevant provisions.
Shao Information Disclosure Obligation.
Kun jeg som leser det som det er basicly approved, eller er det pga google translate at det ser slik ut?
âwhen wasâ, og ikke âwhen willâ
Kommentar fra user der:
2 Likes
Det er trolig en formalitet, men sÄ er det det med Ä selge bjÞrn fÞr skinnet er skutt. Ikke ofte man ser analytikere operere med 90+ % for godkjenning.
3 Likes
Riktig, det er en formalitet. Ingen grunn til at NMPA gÄr imot anbefalingen til CDE. Det er mer en administrativ prosess NMPA utfÞrer nÄ. NÄ er halvparten av tidsfristen brukt. Any day now.
5 Likes
Det er jo typisk vĂ„r âflaksâ hvis avgjĂžrelsen kommer akkurat nĂ„ som den oransje galningen er i ferd med Ă„ skape kaos pĂ„ bĂžrsene.
Ned Ă„ teste 70.6 my bet.
Bra Asia leverer i sÄ fall da. Artig at noen har ment at Asia var en risiko. Plutselig en styrke med Asia nÄ!
PHO er snarere veldig dyktige eller heldige med sin partneravtale med Asia selskap i bioteknologi sektoren
1 Like
Dundrer ned pÄ tungt volum 
FÄr hÄpe at det ikke er not approved som ligger til grunn for det da.
Tror du hadde sett det pÄ Asieris fÞr PHO-kursen, for Ä si det slik 
Jeg var for Ăžvrig ironisk mtp. volum, det er bĂžss.
1 Like
Lolz, jeg trodde av en eller annen grunn at du henviste til QAsieris. My bad. 
Jeg er bare sÄ veldig spent pÄ hva kursen bykser til ved godkjenning. FÄr vi toppnoteringen umiddelbart eller etter 3 dagers regelen?
Har hele tiden vÊrt Êrlig pÄ at jeg planlegger exit da.
Har trua men nÄ rÞrer det seg vanvittig i andre bransjer.
Kanskje tilbake om et Ă„r eller to. Hvem vet